Depression

Here are highlights from the week in Psychiatric Times.

A poster presented at the 2024 ASCP Annual Meeting discussed the results of a study on the treatment for depressive symptoms in this patient population.

How effective is this treatment in real-world clinical settings? Experts explore this in a poster presented at the 2024 ASCP Annual Meeting.

A poster presented at the 2024 ASCP Annual Meeting discussed the results of a study analyzing the treatment’s safety and efficacy in this patient population.

A poster presented at the 2024 ASCP Annual Meeting discusses the results of a systematic literature review.

What can 2 recent deaths show us about depression and suicidality?

How can we enhance our lithium research?

Here are highlights from the week in Psychiatric Times.

The latest in mood disorder news, all in one place.

What is new in research on postpartum depression?

Here’s a look at our recent coverage of these disorders in honor of Mother’s Day 2024.

Here are highlights from the third day of this year’s APA Annual Meeting.

Here are highlights from the second day of this year’s APA Annual Meeting.

This 2024 APA Annual Meeting poster investigated the relationship between antiobesity agents like semaglutide and depression.

Here are some updates from the world of psychiatry throughout the month of April.

The experts weighed in on a wide variety of psychiatric issues for the April issue of Psychiatric Times.

Here are highlights from the week in Psychiatric Times.

What is new in research on posttraumatic stress disorder?

What are the connections between what we eat and disorders such as anxiety and depression?

Check out new positive topline data from the SAVITRI study assessing the efficacy and safety of NBI-1065845 in adults with major depressive disorder.

Here are highlights from the week in Psychiatric Times.

What does the recent FDA clearance of this treatment for adolescents mean for the future of MDD treatment?

Study results suggest the potential for a scalable, single-dose treatment approach.

Recent research investigated the benefits and risks of augmentation compared with switching strategies for TRD in older adults.

Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints of a new phase 3 study.